Chinese Journal of Cancer Research

, Volume 24, Issue 4, pp 361–367 | Cite as

Proton therapy for hepatocellular carcinoma

  • Ted C. Ling
  • Joseph I. Kang
  • David A. Bush
  • Jerry D. Slater
  • Gary Y. Yang
Review Article


Proton radiotherapy has seen an increasing role in the treatment of hepatocellular carcinoma (HCC). Historically, external beam radiotherapy has played a very limited role in HCC due to a high incidence of toxicity to surrounding normal structures. The ability to deliver a high dose of radiation to the tumor is a key factor in improving outcomes in HCC. Advances in photon radiotherapy have improved dose conformity and allowed dose escalation to the tumor. However, despite these advances there is still a large volume of normal liver that receives a considerable radiation dose during treatment. Proton beams do not have an exit dose along the beam path once they enter the body. The inherent physical attributes of proton radiotherapy offer a way to maximize tumor control via dose escalation while avoiding excessive radiation to the remaining liver, thus increasing biological effectiveness. In this review we discuss the physical attributes and rationale for proton radiotherapy in HCC. We also review recent literature regarding clinical outcomes of using proton radiotherapy for the treatment of HCC.

Key words

Proton radiotherapy hepatocellular carcinoma (HCC) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5–S16.PubMedCrossRefGoogle Scholar
  2. 2.
    Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Jiang X, Pan SY, de Groh M, et al. Increasing incidence in liver cancer in Canada, 1972–2006: Age-period-cohort analysis. J Gastrointest Oncol 2011;2:223–231.PubMedGoogle Scholar
  4. 4.
    Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010;15:23–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237–257.PubMedGoogle Scholar
  6. 6.
    Al Ustwani O, Iancu D, Yacoub R, et al. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol 2012;3:97–104.PubMedGoogle Scholar
  7. 7.
    Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 2004;11:298–303.PubMedCrossRefGoogle Scholar
  8. 8.
    Page AJ, Kooby DA. Perioperative management of hepatic resection. J Gastrointest Oncol 2012;3:19–27.PubMedGoogle Scholar
  9. 9.
    Aragon RJ, Solomon NL. Techniques of hepatic resection. J Gastrointest Oncol 2012;3:28–40PubMedGoogle Scholar
  10. 10.
    May KS, Yang GY, Khushalani NI, et al. Association of Technetium (99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies. J Gastrointest Oncol 2010;1:7–15.PubMedGoogle Scholar
  11. 11.
    Munireddy S, Katz S, Somasundar P, et al. Thermal tumor ablation therapy for colorectal cancer hepatic metastasis. J Gastrointest Oncol 2012;3:69–77.PubMedGoogle Scholar
  12. 12.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917.PubMedCrossRefGoogle Scholar
  13. 13.
    Bruix J, Sherman M, Practice Guidelines Committee, et al. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.PubMedCrossRefGoogle Scholar
  14. 14.
    Matsuzaki Y. Powerful radiotherapy for hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025–1033.CrossRefGoogle Scholar
  15. 15.
    Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000;47:435–442.PubMedCrossRefGoogle Scholar
  16. 16.
    Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18:2210–2218.PubMedGoogle Scholar
  17. 17.
    Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150–155.PubMedCrossRefGoogle Scholar
  18. 18.
    Schulte RW, Wore AJ. New developments in treatment planning and verification of particle beam therapy. Transl Cancer Res 2012;1:184–195.Google Scholar
  19. 19.
    Wang X, Krishnan S, Zhang X, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 2008 Winter;33:259–267.PubMedCrossRefGoogle Scholar
  20. 20.
    Petersen JB, Lassen Y, Hansen AT, et al. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. Acta Oncol 2011;50:823–828.PubMedCrossRefGoogle Scholar
  21. 21.
    Mizumoto M, Okumura T, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 2011;81:1039–1045.PubMedCrossRefGoogle Scholar
  22. 22.
    Li Z. Toward robust proton therapy planning and delivery. Transl Cancer Res 2012;1:217–226.Google Scholar
  23. 23.
    Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 1999;50:135–142.PubMedCrossRefGoogle Scholar
  24. 24.
    Dale RG, Jones B, Cárabe-Fernández A. Why more needs to be known about RBE effects in modern radiotherapy. Appl Radiat Isot 2009;67:387–392.PubMedCrossRefGoogle Scholar
  25. 25.
    Fukumitsu N, Hashimoto T, Okumura T, et al. Investigation of the geometric accuracy of proton beam irradiation in the liver. Int J Radiat Oncol Biol Phys 2012;82:826–833.PubMedCrossRefGoogle Scholar
  26. 26.
    Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810–821.PubMedCrossRefGoogle Scholar
  27. 27.
    Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103–110.PubMedCrossRefGoogle Scholar
  28. 28.
    Mizumoto M, Okumura T, Hashimoto T, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012;82:e529–e535.PubMedCrossRefGoogle Scholar
  29. 29.
    Kanemoto A, Mizumoto M, Okumura T, et al. Dosevolume histogram analysis for risk factors of radiationinduced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma. Acta Oncol 2012. [Epub ahead of print].Google Scholar
  30. 30.
    Komatsu S, Hori Y, Fukumoto T, et al. Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma. World J Gastroenterol 2010;16:1800–1803.PubMedCrossRefGoogle Scholar
  31. 31.
    Ling TC, Kang JI, Slater JD, et al. Proton therapy for gastrointestinal cancers. Transl Cancer Res 2012;1:150–158.Google Scholar
  32. 32.
    Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005;11:3799–3805.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;76:460–466.PubMedCrossRefGoogle Scholar
  34. 34.
    Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009;115:5499–5506.PubMedCrossRefGoogle Scholar
  35. 35.
    Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011;117:4890–4904.PubMedCrossRefGoogle Scholar
  36. 36.
    Sugahara S, Nakayama H, Fukuda K, et al. Protonbeam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009;185:782–788.PubMedCrossRefGoogle Scholar
  37. 37.
    Hashimoto T, Tokuuye K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;65:196–202.PubMedCrossRefGoogle Scholar
  38. 38.
    Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839–1846.PubMedCrossRefGoogle Scholar
  39. 39.
    Nakayama H, Sugahara S, Fukuda K, et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. Int J Radiat Oncol Biol Phys 2011;80:992–995.PubMedCrossRefGoogle Scholar
  40. 40.
    Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009;74:831–836.PubMedCrossRefGoogle Scholar
  41. 41.
    Bush DA, Hillebrand DJ, Slater JM, et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127:S189–S193.PubMedCrossRefGoogle Scholar
  42. 42.
    Bush DA, Kayali Z, Grove R, et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011;117:3053–3059.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Ted C. Ling
    • 1
  • Joseph I. Kang
    • 1
  • David A. Bush
    • 1
  • Jerry D. Slater
    • 1
  • Gary Y. Yang
    • 1
    • 2
  1. 1.Department of Radiation MedicineLoma Linda University Medical CenterLoma LindaUSA
  2. 2.Department of Radiation MedicineLoma Linda University Medical CenterLoma LindaUSA

Personalised recommendations